CYP3A4 and pulmonary arterial hypertension: Prior to changing pulmonary hypertension medications from bosentan to macitentan, bosentan could have increased the hepatic metabolism of warfarin by inducing CYP2C9 and CYP3A4 activity and decreasing its anticoagulant effects.